
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Biotechnology · market cap $3.0B
Research and calibrated estimates, not financial advice — verify before acting.
No upcoming catalysts in our calendar.
| Asset | Phase | Indication |
|---|---|---|
| Relaxin | Phase 3 | Heart Failure, Congestive |
| Tavokinogene Telseplasmid (tavo) | Phase 2 | Melanoma |
| Oxytocin 100 i.u. | Phase 2 | Vaginal Atrophy |
| Isoflurane | Phase 3 | Sedation |
| Oxytocin 400 IU vaginal gel | Phase 2 | Vulvovaginal Atrophy |
| Aramchol | Phase 2 | Non-Alcoholic Fatty Liver Disease |
| Ibuprofen and Aprepitant | Phase 3 | Primary Dysmenorrhea |
| Sevre-Long™ | Phase 3 | Opiate Dependent |
| Oxytocin | Phase 2 | Atrophy |
| Midazolam | Phase 3 | Sedation |
| FX06 | Phase 2 | Myocardial Ischemia |
| Active Theramine and Active Naproxen | Phase 3 | Low Back Pain |
| GDC 268 Lotion | Phase 3 | Acne Vulgaris |
| low-dose group (naltrexone implant 0.9 g + general supportive psychological counseling) | Phase 2 | AUD |
| IVACFLU-S | Phase 3 | Influenza, Human |
| GDC-229 | Phase 3 | Bacterial Vaginosis |
| EPODURE (dermal Biopump for erythropoietin) | Phase 2 | Anemia |
| Tadalafil 5mg (Male) | Phase 3 | Erectile Dysfunction |
| Glyceryl trinitrate | Phase 2 | Erectile Dysfunction |
| Osteodex | Phase 2 | Prostate Cancer Metastatic |
Daily closes through 2026-01-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.